Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Jun

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors

New Research Links Low Alcohol Consumption to Elevated Health Risks

Digital Tool May Improve Patient Engagement in Oncology Clinical Trials

GLP-1 RAs May Reduce Risk of Obesity-Related Cancers

Teclistamab in Previously Treated Multiple Myeloma